Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGAM | O43451 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SI | P14410 | 1/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28696630 | 0.83 | MGAM (0.46) | MGAMGAASIMGAM2L3MBTL1 | |
| SCHEMBL7428536 | 0.83 | MGAM (0.46) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL17725604 | 0.82 | TSHR (0.48) | MGAMGAASIMGAM2KMT2A | |
| SCHEMBL4464939 | 0.82 | GAA (0.59) | MGAMGAASIMGAM2CYP1A2 | |
| Hydrochloric Acid SCHEMBL7567529 | 0.81 | MGAM (0.45) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL15391903 | 0.81 | GAA (0.48) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL11119128 | 0.80 | L3MBTL1 (0.44) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL22223252 | 0.80 | MGAM (0.43) | MGAMGAASIMGAM2CYP1A2 | |
| SCHEMBL11231751 | 0.80 | CYP1A2 (0.44) | MGAMGAASIMGAM2CYP1A2 | |
| Hydrochloric Acid SCHEMBL11851530 | 0.80 | GAA (0.56) | MGAMGAASIMGAM2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12077510-B2 | Carboxylic acid compounds | Sumitomo Pharma Co., Ltd. (JP) | 2024-09-03 | — | — | US | disclosed |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-08-25 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-11299465-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-12 | — | — | US | disclosed |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-08 | — | — | US | disclosed |
| US-10562861-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-10562861-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-02-18 | — | — | US | disclosed |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-04-25 | — | — | US | disclosed |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-9376398-B2 | Carboxylic acid compounds | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2016-06-28 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | Sumitomo Pharma Co., Ltd. (JP) | 2015-04-09 | — | — | US | disclosed |
| CN-104302628-A | Carboxylic acid compounds | DAINIPPON SUMITOMO PHARMA CO | 2015-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099770-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | MGAM 1677/4885GAA 181/4885SI 1366/4885 |
| US-20160251319-A1 | CARBOXYLIC ACID COMPOUNDS | C9, SUCNR1, C3AR1 | MGAM 1677/4885GAA 181/4885SI 1366/4885 |
| US-12077510-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
| US-20200317623-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
| US-20190119220-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
| US-11299465-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
| US-20220267282-A1 | CARBOXYLIC ACID COMPOUNDS | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
| US-10562861-B2 | Carboxylic acid compounds | C9, C3AR1, SUCNR1 | MGAM 1508/4885GAA 225/4885SI 1255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.